Navigation Links
Johnson & Johnson Reports 2013 Second-Quarter Results:
Date:7/16/2013

siness," said Alex Gorsky, Chairman and Chief Executive Officer.  "Our talented colleagues at Johnson & Johnson continue to bring meaningful innovations to patients and consumers around the world and have positioned us well to deliver sustainable growth."

The Company increased its earnings guidance for full-year 2013 to $5.40 - $5.47 per share. The Company's guidance excludes the impact of special items.

Worldwide Consumer sales of $3.7 billion for the second quarter represented an increase of 1.1% versus the prior year consisting of an operational increase of 1.7% and a negative impact from currency of 0.6%.  Domestic sales increased 1.0%.  International sales increased 1.1%, which reflected an operational increase of 2.0% and a negative currency impact of 0.9%.

Positive contributors to operational results were upper respiratory over-the-counter medicines; TYLENOL® and MOTRIN® analgesics; international sales of LISTERINE® mouthwash; baby care products and women's sanitary protection products.

Worldwide Pharmaceutical sales of $7.0 billion for the second quarter represented an increase of 11.7% versus the prior year with operational growth of 12.9% and a negative impact from currency of 1.2%.  Domestic sales increased 9.1%.  International sales increased 14.1% which reflected an operational increase of 16.5% and a negative currency impact of 2.4%. 

Primary contributors to operational sales growth were REMICADE® (infliximab) and SIMPONI® (golimumab),  biologics approved for the treatment of a number of immune-mediated inflammatory diseases; STELARA® (ustekinumab), a biologic approved for the treatment of moderate to severe plaque psoriasis; INVEGA® SUSTENNA®/XEPLION® (paliperidone palmitate), a once-monthly, long-acting, injectable atypical antipsych
'/>"/>

SOURCE Johnson & Johnson
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24

Related medicine technology :

1. Johnson & Johnson Announces Definitive Agreement To Acquire Aragon Pharmaceuticals, Inc.
2. Janssen and Johnson & Johnson to Provide Webcast Presentation of Simeprevir Phase 3 Clinical Data Presented at The International Liver Congress of the European Association for the Study of the Liver (EASL)
3. Johnson & Johnson to Host Pharmaceuticals Business Review
4. Johnson & Johnson Announces Sale of Elan American Depositary Shares to Elan
5. Johnson Electric Launches Medication Dosing Systems
6. Johnson & Johnson to Host Analyst Conference Call on First-Quarter Results
7. Johnson & Johnson gibt Eröffnung des Innovationszentrums in London bekannt
8. Johnson & Johnson Announces Opening of London Innovation Centre
9. Kevin Johnson Joins United Allergy Services Board Of Directors
10. Free Research Report on Delta Air Lines, Inc., Johnson & Johnson, Barrick Gold Corp., Exelon Corp. and Cirrus Logic, Inc.
11. Huntington Memorial Hospital Elects Paul Johnson, Deborah Williams to its Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/30/2014)... , Oct. 30, 2014  Misonix, Inc. (NASDAQ: ... that designs, manufactures and markets innovative therapeutic ultrasonic instruments ... today that it will report financial results for the ... 2014. The Company has scheduled a conference call that ... ET to review the results. Interested ...
(Date:10/30/2014)... Oct. 30, 2014  Zimmer Holdings, Inc. (NYSE: ... future executive leadership team and organizational structure of the ... Zimmer also announced that the combined organization will leverage ... named Zimmer Biomet, with the new brand to be ... of the merger.  The future leadership team is committed ...
(Date:10/30/2014)... 2014  The number of retail health clinics in ... steadily, thanks to drug store chains, according to Kalorama ... economic downturn, retail clinic growth had been at a ... the number of retail clinics reached nearly 1,600 according ... Market Overview and 2014 Consumer Survey Results .  ...
Breaking Medicine Technology:Misonix, Inc. To Report First Quarter Fiscal Year 2015 Financial Results On Thursday, November 6, 2014 2Zimmer Announces Executive Leadership Team and New Name of Combined Company Following Closing 2Zimmer Announces Executive Leadership Team and New Name of Combined Company Following Closing 3Zimmer Announces Executive Leadership Team and New Name of Combined Company Following Closing 4Zimmer Announces Executive Leadership Team and New Name of Combined Company Following Closing 5Zimmer Announces Executive Leadership Team and New Name of Combined Company Following Closing 6Zimmer Announces Executive Leadership Team and New Name of Combined Company Following Closing 7Zimmer Announces Executive Leadership Team and New Name of Combined Company Following Closing 8Zimmer Announces Executive Leadership Team and New Name of Combined Company Following Closing 9Report: Drugstore Chains Drive Retail Clinic Growth 2Report: Drugstore Chains Drive Retail Clinic Growth 3
... SAN DIEGO, Dec. 9, 2011 Gen-Probe Incorporated (NASDAQ: ... Oppenheimer 22nd Annual Healthcare Conference in New York on December 14, ... to be webcast live and may be accessed through a link ... The webcast will be available for 30 days following the event. ...
... 9, 2011  Sister Carol Keehan, DC, president and chief ... United States (CHA), issued the following statement. ... Secretary Kathleen Sebelius for her intelligent and courageous decision ... unsupervised the strong hormone contained in the drug known ...
Cached Medicine Technology:Gen-Probe to Webcast Presentation at the Oppenheimer 22nd Annual Healthcare Conference 2Catholic Health Association Applauds HHS Decision on Plan B 2
(Date:10/30/2014)... new treatments for injuries and damage to the joints, ... example, is a hard material that caps the ends ... Davis biomedical engineers, exploring ways to toughen up engineered ... report new developments this week in the journal ... "The problem with engineered tissue is that the mechanical ...
(Date:10/30/2014)... group at the DFG Research Center for Regenerative Therapies ... (CRTD) demonstrated for the first time the in vitro ... dimensions from mouse embryonic stem cells. Correct spatial organization ... dorsal/ventral axis was observed., This study has been published ... Reports " on 30.10.2014 ., For many years Elly ...
(Date:10/30/2014)... Timothy, InstaKNOT’s 4-year-old CEO, plans ... that you are never too young to give back ... and Carl at the 2013 Santa Arriving By Helicopter ... Chamber of Commerce. Tracey gave Timothy a special tour ... his real fireman’s hat, and extending an offer to ...
(Date:10/30/2014)... Diego, Calif. (PRWEB) October 30, 2014 ... longer mutually exclusive concepts in the medical-grade skin ... on the development of uniquely potent topical dermatological ... Health System ( http://www.RefinitySkinScience.com ) with patented COSMEDERM®-7 ... available glycolic acid concentrations (50% and 70%) and ...
(Date:10/30/2014)... Paramount Rx, a full-service prescription benefits ... to help people save money through its innovative discount ... prescription drugs in the new health care system, the ... bridge the relationship between consumers, businesses and the pharmacy ... people face today with medical costs is the rising ...
Breaking Medicine News(10 mins):Health News:Making lab-grown tissues stronger 2Health News:Reconstruction of a patterned piece of spinal cord in 3-D culture 2Health News:4-year-old InstaKNOT CEO Honors Local Firefighters with Community Support 2Health News:4-year-old InstaKNOT CEO Honors Local Firefighters with Community Support 3Health News:4-year-old InstaKNOT CEO Honors Local Firefighters with Community Support 4Health News:Cosmederm Redefines Peel Science Standard with Launch of Refinity® Skin Health System 2Health News:Cosmederm Redefines Peel Science Standard with Launch of Refinity® Skin Health System 3Health News:Cosmederm Redefines Peel Science Standard with Launch of Refinity® Skin Health System 4Health News:Paramount Rx Discount Card Program Provides Valuable Resources in Midst of Current Health Care Reform 2Health News:Paramount Rx Discount Card Program Provides Valuable Resources in Midst of Current Health Care Reform 3
... Md., Nov. 9 Human Genome Sciences,Inc. (Nasdaq: ... JMP,Securities Sector Focus Conference will be webcast and may ... ) A member of Human Genome Sciences, ... on Tuesday, November 13, 2007 at 4:30 pm Eastern,Time. ...
... Calif., Nov. 9 Masimo (Nasdaq: MASI ),the ... Perfusion,pulse oximetry, announced today that the Pricing Committee of ... plan. "This plan is designed to enhance the ... control of the company,that do not offer an adequate ...
... SGP ) will provide a live audio webcast of ... chief financial,officer, at the 2007 Credit Suisse Health Care ... a.m. (MST) (1 p.m. EST). A live audio ... to,the Investor Relations section of the Schering-Plough corporate Web ...
... The American Stock Exchange LLC(R),(Amex(R)) announced today its final ... Health Sciences, Inc. from listing on the,Exchange, and filed ... from,listing with the Securities and Exchange Commission (the "SEC"). ... postponed by,the SEC. Pursuant to its rules, the ...
... CHICAGO (November 9, 2007) A gender difference exists ... they evaluate the factors that may influence their career ... in the November issue of the Journal of the ... a significantly higher percentage of women than men were ...
... from the University of Alabama at Birmingham (UAB) ... common anti-HIV drugs can prevent HIV-positive pregnant women ... drugs, potentially improving future treatment options., Providing tenofovir ... the extent of resistance to non-nucleoside reverse transcriptate ...
Cached Medicine News:Health News:Masimo Corporation Adopts Stockholder Rights Plan 2Health News:Masimo Corporation Adopts Stockholder Rights Plan 3Health News:Survey shows gender differences are factor when surgeons in training choose a subspecialty 2Health News:HIV drug resistance risk in mothers reduced by combination of common drugs 2
... procedures are now greatly improved with Volk's ... new lens promotes precise and focused laser ... optimized for enhanced viewing and laser treatment ... design comes standard with LaserWindow for optimal ...
... Super Macula® 2.2 offers extremely high resolution ... while achieving an exceptionally wide 78° field ... choice for critical evaluation of the optic ... detailed views of the macula and disc. ...
... Volk Area Centralis® is excellent for ... and changes from macular degeneration, retinal ... diabetic retinopathy and other retinal conditions. ... treatment of these conditions providing excellent ...
... The original 130° QuadrAspheric lens has ... 1989 as the preferred wide field fundus ... provides a definite advantage over competitive wide ... displacement, and ease of use. This lens ...
Medicine Products: